Editorial: Toll-like receptor expression in irritable bowel syndrome: On the alert for a microbial threat

American Journal of Gastroenterology

Volumn 106, Issue 2, 2011, Pages 337-339

  Barbara, Giovanni ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

HUMAN; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; MICROFLORA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

BIOPSY; BLOTTING, WESTERN; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNITY, INNATE; IRRITABLE BOWEL SYNDROME; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTORS;

EID: 79751494991     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.440     Document Type: Review

References (32)

1. Barbara G, Stanghellini V. Biomarkers in IBS: when will they replace symptoms for diagnosis and management? Gut 2009; 58: 1571-5.
2. Ohman L, Simr én M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-73.
3. Saito YA, Mitra N, Mayer EA. Genetic approaches to functional gastrointestinal disorders. Gastroenterology 2010; 138: 1276-85.
4. Piche T, Barbara G, Aubert P et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196-201.
5. Coë ffi er M, Gloro R, Boukhettala N et al, Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol, 2010, 105: 1181-8.
6. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397-414. (Pubitemid 46127672)
7. Cremon C, Carini G, De Giorgio R et al. Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon? Expert Rev Mol Diagn 2010; 10: 389-93.
8. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702. (Pubitemid 38298317)
9. Cremon C, Gargano L, Morselli-Labate AM et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400.
10. Weston AP, Biddle WL, Bhatia PS et al. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993; 38: 1590-5. (Pubitemid 23271411)
11. Guilarte M, Santos J, De Torres I et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203-9.
12. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009; 146: 41-6.
13. Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37. (Pubitemid 46108761)
14. Cenac N, Andrews CN, Holzhausen M et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117: 636-47. (Pubitemid 46348522)
15. Buhner S, Li Q, Vignali S et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137: 1425-34.
16. Gecse K, R ó ka R, Ferrier L et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008; 57: 591-9.
17. Villani AC, Lemire M, Th abane M et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010; 138: 1502-13.
18. Aerssens J, Camilleri M, Talloen W et al. Alterations in mucosal immunity identifi ed in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 194-205. (Pubitemid 351172944)
19. Corinaldesi R, Stanghellini V, Cremon C et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009; 30: 245-52.
20. Klooker TK, Braak B, Koopman KE et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010; 59: 1213-21.
21. Pimentel M, Park S, Mirocha J et al. The Effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145: 557-63. (Pubitemid 46780934)
22. Moayyedi P, Ford AC, Talley NJ et al. The Efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-32.
23. Brint EK, MacSharry J, Fanning A et al. Diff erential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterology 2011;106:329-36 (this issue).
24. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009; 22: 240-73.
25. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis 2010; 16: 1583-97.
26. Dlugosz A, T ö rnblom H, Mohammadian G et al. Chlamydia trachomatis antigens in enteroendocrine cells and macrophages of the small bowel in patients with severe irritable bowel syndrome. BMC Gastroenterol 2010; 10: 19.
27. Schoepfer AM, Schaffer T, Seibold-Schmid B et al. Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 2008; 20: 1110-8.
28. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update 2005; 11: 411-23. (Pubitemid 40895468)
29. Macsharry J, O'Mahony L, Fanning A et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008; 43: 1467-76.
30. Langhorst J, Junge A, RuEffer A et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104: 404-10.
31. Vora P, Youdim A, Th omas LS et al. Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol 2004; 173: 5398-405. (Pubitemid 39392123)
32. Romano Carratelli C, Mazzola N, Paolillo R et al. Toll-like receptor-4 (TLR4) mediates human beta-defensin-2 (HBD-2) induction in response to Chlamydia pneumoniae in mononuclear cells. FEMS Immunol Med Microbiol 2009; 57: 116-24 .